AVIR - Company ID 0001593899
The table below shows Atea Pharmaceuticals, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $76.55M | $79.32M | $77.34M | $87.72M | $119.39M | $98.46M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $228.66M |
| $263.20M |
| $336.14M |
| $385.60M |
| $433.71M |
| $486.91M |
| Property, plant & equipment | $249.00K | $353.00K | $561.00K | $665.00K | $769.00K | $977.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $232.28M | $267.08M | $342.96M | $391.61M | $439.96M | $490.96M |
| Accounts payable | $10.06M | $9.45M | $3.52M | $8.84M | $7.39M | $5.79M |
| Total current liabilities | $28.12M | $33.37M | $20.18M | $20.12M | $21.75M | $25.19M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | - | - | $27.18M | $27.19M | $28.88M | $32.44M |
| Retained earnings | -$600.94M | -$568.01M | -$477.70M | -$435.65M | -$398.49M | -$330.68M |
| Total equity | $204.16M | $233.71M | $315.78M | $364.42M | $411.08M | $458.52M |